SYK and post-transplant lymphoproliferative disease: According to Hatton et al. [34], in PTLD-derived EBV-positive B cells, LMP2A activates Syk and prevents the loss of X-linked inhibitor of apoptosis protein (XIAP) through the PI3K/AKT signaling pathway to maintain cell survival, while administration of Syk and PI3K/AKT inhibitors can induce cell apoptosis.